Elsevier

Current Opinion in Biotechnology

Volume 60, December 2019, Pages iii-v
Current Opinion in Biotechnology

Editorial overview: Pharmaceutical biotechnology: new frontiers in protein, gene, and cell therapies

https://doi.org/10.1016/j.copbio.2019.09.022Get rights and content

Section snippets

Dr Yvonne Chen is an Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles. Before joining UCLA in 2013, Yvonne was a Junior Fellow in the Harvard Society of Fellows. She received her B.S. and Ph.D. in Chemical Engineering from Stanford University and Caltech, respectively. The Chen lab’s work on engineering next-generation T-cell therapies for cancer has been recognized by the NIH Director’s Early Independence Award, the NSF CAREER

References (0)

Cited by (0)

Dr Yvonne Chen is an Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles. Before joining UCLA in 2013, Yvonne was a Junior Fellow in the Harvard Society of Fellows. She received her B.S. and Ph.D. in Chemical Engineering from Stanford University and Caltech, respectively. The Chen lab’s work on engineering next-generation T-cell therapies for cancer has been recognized by the NIH Director’s Early Independence Award, the NSF CAREER Award, the ACGT Young Investigator Award in Cell and Gene Therapy for Cancer, the Mark Foundation Emerging Leader Award, and the Cancer Research Institute Lloyd J. Old STAR Award.

Dr Van Deventer completed undergraduate studies at Stanford University, Ph.D. studies at the California Institute of Technology, and postdoctoral work at the Massachusetts Institute of Technology. Dr Van Deventer is currently an Assistant Professor at Tufts University with a primary appointment in Chemical and Biological Engineering and an adjunct appointment in Biomedical Engineering. The Van Deventer Laboratory works at the interface of protein engineering, synthetic biology, and chemical biology. Primary interests of the group include engineering cells to better accommodate alternative genetic codes and integrating noncanonical amino acids into protein engineering strategies in search of new classes of therapeutics. Dr Van Deventer was recently awarded an R35 Outstanding Investigator Award for Early Career Researchers via the National Institute of General Medical Sciences at the National Institutes of Health.

View full text